PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
96.69%
Cash & equivalents growing 96.69% while GNPX's declined -35.26%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
96.69%
Below half of GNPX's -35.26%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
119.86%
Other current assets growth < half of GNPX's 746.52%. David Dodd sees a leaner approach to short-term items.
94.31%
Below half of GNPX's -17.66%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-6.34%
1.25-1.5x GNPX's -4.58%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.92%
Below half of GNPX's 7.35%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
78.33%
Below half of GNPX's -16.22%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-11.61%
Less than half of GNPX's 325.36%. David Dodd sees a more disciplined AP approach or lower volume.
-42.55%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
11.61%
Higher Deferred Revenue (Current) Growth compared to GNPX's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-11.56%
Less than half of GNPX's 306.25%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.36%
Higher Total Non-Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-11.23%
Less than half of GNPX's 306.25%. David Dodd sees far fewer liability expansions relative to competitor.
36.01%
Above 1.5x GNPX's 1.55%. Michael Burry suspects heavy new equity expansion or dilution.
-2.61%
Below half GNPX's -11.55%. Michael Burry suspects major net losses or high dividends vs. competitor.
-6.95%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
193.87%
Below half GNPX's -26.50%. Michael Burry sees potential underperformance in building shareholder capital.
78.33%
Below half GNPX's -16.22%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-9.95%
Less than half of GNPX's 147.52%. David Dodd sees less overall debt expansion vs. competitor.
-116.79%
Less than half of GNPX's 35.92%. David Dodd sees better deleveraging or stronger cash buildup than competitor.